Bridgebio Pharma Inc. (bbio 2.25 02/01/29)
13F holders, Q2 2025 (June 30)5holders
0new positions
0sold out
$0.94avg. 13F price*
At the end of Q2 2025, 5 institutions reported holding Bridgebio Pharma Inc. (bbio 2.25 02/01/29) in their 13F filings, unchanged from Q1 2025. 0 opened new positions and 0 sold out. The largest holders were HighTower Advisors, LLC ($3.7M), New York State Common Retirement Fund ($2.8M) and BNP PARIBAS ASSET MANAGEMENT Holding S.A. ($2.4M).
- Company
- Bridgebio Pharma Inc. (bbio 2.25 02/01/29)
- CUSIP
- 10806XAD4
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q1 2025 → Q2 2025: 267,001 shares bought, net +267,001 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| HighTower Advisors, LLC | 0.00% | No change | 4,014,000 | $3.7M |
| New York State Common Retirement Fund | 0.00% | Add +6.4% | 3,056,000 | $2.8M |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 0.01% | Add +0.0% | 2,500,000 | $2.4M |
| Sei Investments Co. | 0.00% | Add +43.4% | 271,000 | $252K |
| Bank of New York Mellon Corp | 0.00% | No change | 200,000 | $187K |
"% of holder's portfolio" is BRIDGEBIO PHARMA INC (BBIO 2.25 02/01/29)'s weight in each manager's 13F, not the share of Bridgebio Pharma Inc. (bbio 2.25 02/01/29) the manager owns.